Salma Younas

Dr. Salma Younas


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2025 in Cureus
Verified
Journal Article
Open access
PDF file
IMIshani Mehta
Ishani Mehta
KJKeshav Juneja
Keshav Juneja
TNTharun Nimmakayala
Tharun Nimmakayala
LBLajpat Bansal
Lajpat Bansal
SPShivani Pulekar
Shivani Pulekar
SYSalma Younas
Salma Younas
The human gut flora of trillions of bacteria is vital for general health and greatly influences digestion, immune system function, and brain development. Through neuronal, hormonal, and immunological channels, the gut-brain axis (GBA), a bidirectional communication network, links the gut microbiota to the central nervous system (CNS). This relationship has been linked to affective diseases, including depression and anxiety, as well as mental health issues. This review explores the intricate relationship between gut bacteria and mood disorders, focusing on how gut microbiota-host interactions, immune system modulation, and neurotransmitter control support mental health. The function of important microbial metabolites, including short-chain fatty acids (SCFAs), in preserving blood-brain barrier integrity and modulating neuroinflammation is covered in this review. It also examines the bidirectional impact between gut health and mental health, including how dysbiosis could aggravate mood disorders and how depressed states might change the composition of gut bacteria. Furthermore, we discuss how psychotropic drugs affect gut flora and consider other elements such as nutrition and lifestyle that affect gut microbiome composition. Potential paths for treating mood disorders through gut microbiota modification are presented as emerging treatment techniques, including probiotics, nutritional therapies, and precision medicine. The development of new therapeutic approaches for mood disorders depends on the awareness of the GBA. Gut bacteria significantly affect mental health through immune modulation, neurotransmitter generation, and other intricate processes. Future studies should concentrate on large, varied populations to better understand these interactions and to create customized treatments that combine gut microbiota modulation with conventional mental health therapies.

3 February 2025 in Cureus
Verified
Journal Article
Open access
PDF file
ABAkshita Bhalla
Akshita Bhalla
ASAnushka Shahi
Anushka Shahi
MMMadhurima Maity
Madhurima Maity
FSFnu Safa
Fnu Safa
VSVindlacheruvu Srividya
Vindlacheruvu Srividya
SYSalma Younas
Salma Younas
Pediatric inflammatory bowel disease (PIBD), including Crohn’s disease and ulcerative colitis, has emerged as a significant global health challenge with rising incidence rates. Unlike adult inflammatory bowel disease, PIBD presents complexities, including growth impairment, nutritional deficiencies, and psychosocial challenges that necessitate tailored management strategies. This article reviews current diagnostic and emerging treatment strategies to highlight the evolution from traditional therapies such as aminosalicylates, corticosteroids, and immunomodulators to advanced biologic agents like infliximab and adalimumab. Emerging biological therapies, including vedolizumab and ustekinumab, show promise, while novel small molecule therapies such as Janus kinase (JAK) inhibitors are under investigation for potential use in the pediatric population. Supportive treatments, including exclusive enteral nutrition, modified diets, and probiotics, play a critical role in comprehensive disease management. Stem cell therapy and fecal microbiota transplant represent innovative approaches still under clinical evaluation. The review underscores the significance of holistic care, incorporating mind-body interventions and psychosocial support to improve patient quality of life. Key challenges persist, such as infection risks associated with long-term biological therapy use, gaps in pediatric-specific guidelines, and the limited inclusion of children in clinical trials. Future recommendations emphasize the importance of structured transition programs bridging pediatric and adult care, regular updates to clinical guidelines, and the integration of precision medicine to personalize treatment plans. Continued research and collaboration are essential for advancing the understanding and management of PIBD, ensuring that pediatric patients benefit from the most effective, evidence-based care available.

20 October 2024 in Cureus
Verified
Journal Article
Open access
PDF file
STSwati Thareja
Swati Thareja
RMRamya Mandapalli
Ramya Mandapalli
FSFahmida Shaik
Fahmida Shaik
APArushee Rajeev Pillai
Arushee Rajeev Pillai
GPGowrishankar Palaniswamy
Gowrishankar Palaniswamy
SYSalma Younas
Salma Younas
Obstructive sleep apnea (OSA) is characterized by recurrent interruptions in breathing during sleep and is associated with a wide range of significant health concerns, particularly cardiovascular complications. This review focuses on the two primary forms of sleep apnea, namely, obstructive and central, with OSA being the most prevalent and commonly linked to conditions, such as hypertension, arrhythmias, and heart failure. Intermittent hypoxemia, activation of the sympathetic nervous system, systemic inflammation, and remodeling of the ventricles are some of the pathophysiological mechanisms that link OSA to cardiovascular disease (CVD). These all lead to higher oxidative stress and endothelial dysfunction. These processes elevate the risk of CVDs, including hypertension, coronary artery disease, and stroke. This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and examined studies published over the last 15 years. The search strategy utilized key terms such as “sleep disorder,” “apnea,” “hypertension,” “cardiovascular disease (CVD),” and “treatment outcomes” across multiple databases, including PubMed, Scopus, Embase, and the Cochrane Library. A total of 128 unique studies were identified, of which 10 met the inclusion criteria and were included in the final analysis. These studies consistently highlighted the significant role OSA plays in exacerbating cardiovascular risks, particularly in patients with comorbid conditions such as obesity, hypertension, and diabetes.

3 February 2025 in Cureus
Verified
Journal Article
Open access
PDF file
SGSheenam Garg
Sheenam Garg
MVMansey Varghese
Mansey Varghese
FSFahmida Shaik
Fahmida Shaik
FJFnu Jatin
Fnu Jatin
DSDheerja Sachdeva
Dheerja Sachdeva
FJFathima Wafa Eranhikkal Jr.
Fathima Wafa Eranhikkal Jr.
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with significant global prevalence and a strong association with metabolic syndrome, obesity, and diabetes. Early diagnosis and prediction of disease progression are critical for effective management. Non-invasive biomarkers have emerged as promising alternatives to liver biopsy, offering safer and more accessible diagnostic and prognostic options. This systematic review evaluates the efficacy of non-invasive biomarkers in diagnosing NAFLD and predicting disease progression, focusing on diagnostic accuracy, clinical utility, and limitations. A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including studies published between 2010 and 2024. Databases such as PubMed, Embase, and Scopus were searched using relevant keywords and Boolean operators. Inclusion criteria comprised studies evaluating adults (18+) with NAFLD using non-invasive biomarkers, compared to liver biopsy or other standards, and reporting diagnostic metrics such as sensitivity, specificity, and area under the curve (AUC). Data were extracted systematically, and study quality was assessed using QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) and the Newcastle-Ottawa Scale. The nine studies include a range of biomarkers such as serum markers (Pro-C3, NIS4), imaging techniques (MRI-PDFF, cT1), and composite scores (cTAG, NFS). Diagnostic accuracy was high, with area under the curve (AUC) values ranging from 0.81 to 0.90 for detecting significant fibrosis and at-risk non-alcoholic steatohepatitis (NASH). Imaging tools such as MRI-PDFF offered superior reproducibility and whole-liver assessments, while composite biomarkers such as NIS4 demonstrated robust sensitivity but moderate specificity. Notable heterogeneity in populations and methodologies was observed. Non-invasive biomarkers show comparable diagnostic performance to liver biopsy while offering significant advantages in safety, scalability, and patient adherence. However, gaps remain, including the need for validation in diverse populations and improved specificity for advanced fibrosis. Integrating non-invasive biomarkers into clinical practice could revolutionize NAFLD management by enabling early diagnosis, guiding treatment, and reducing reliance on invasive methods. Future research should focus on validating these tools across diverse cohorts and developing novel biomarkers to address existing limitations.

24 May 2025
Verified
Book Chapter
Closed access
PDF file
SSSweta Sahu
Sweta Sahu
SBSravani Bhavanam
Sravani Bhavanam
SYSalma Younas
Salma Younas

9 December 2024 in Cureus
Verified
Journal Article
Open access
PDF file
SKSri Meghana Kankipati
Sri Meghana Kankipati
SDSurbhi Dumra
Surbhi Dumra
STSwati Thareja
Swati Thareja
LILyluma Ishfaq
Lyluma Ishfaq
MZMah N. Zargar
Mah N. Zargar
SYSalma Younas
Salma Younas
Berardinelli-Seip congenital lipodystrophy (BSCL), also known as congenital generalized lipodystrophy (CGL), is an exceptionally rare autosomal recessive disorder marked by a significant deficiency of adipose tissue throughout the body. This lack of adipose tissue, normally found beneath the skin and between internal organs, leads to impaired adipocyte formation and fat storage, causing lipids to accumulate in atypical tissues such as muscles and the liver. The extent of adipose tissue loss directly influences the severity of symptoms, which can include a muscular appearance, increased appetite, bone cysts, marrow fat depletion, acromegalic features, severe insulin resistance, skeletal muscle hypertrophy, hypertrophic cardiomyopathy, hepatic steatosis, hepatomegaly, cirrhosis, and intellectual disability. We present a case series of two siblings with BSCL: a nine-year-old boy and his seven-year-old sister, each with unique manifestations of the disorder. The older sibling presented with high-grade fever and right ankle pain, possibly indicative of a calcified deposit, alongside complications such as hyperglycemia (managed without insulin) and moderate pulmonary arterial hypertension (PAH) with tricuspid regurgitation (TR). The younger sibling displayed similar metabolic and cardiovascular complications, including hepatomegaly and early signs of cardiac involvement. Both cases required comprehensive evaluations, revealing anemia, thrombocytopenia, elevated leukocyte count, and high C-reactive protein (CRP) levels. The children were managed with high-potency antibiotics, leading to a marked improvement in their overall conditions. These cases demonstrate the broad spectrum of clinical manifestations associated with BSCL and highlight the importance of a multidisciplinary approach for effective management. Although limited by the small sample size, this case series shows the importance of a multidisciplinary approach in addressing the complex and overlapping symptoms of BSCL, which often mimic more common conditions. Increased awareness among healthcare providers is crucial for ensuring timely diagnosis and appropriate intervention, particularly in pediatric patients.